- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Brain Training (Active), Brain Training (Passive), Brain Training (Active or Passive)
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 535
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Snake Envenomation
- Interventions
- Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy), Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy), Placebo
- Biological
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 12 Months and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 4
- States / cities
- Charlotte, North Carolina • Durham, North Carolina • Columbia, South Carolina + 1 more
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 804 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 341
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
- Conditions
- Schizophrenia
- Interventions
- SEP-380135, Quinidine Gluconate
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Schizophrenia
- Interventions
- LY2140023, Placebo, Standard of Care
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more
- Conditions
- Heart Failure, Obesity, Type 2 Diabetes Mellitus, Health Normal Volunteer Subjects
- Interventions
- [18F]FluorbetaOx
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Human Immunodeficiency Virus, Chronic Neuropathic Pain
- Interventions
- Low Dose Naltrexone
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Psychological Distress, Psychological Well-being, Subjective Health, Injuries
- Interventions
- Health and Well-being Committee
- Behavioral
- Lead sponsor
- Massachusetts Institute of Technology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
- Interventions
- LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- 4D-125 IVT Injection, Observational
- Biological · Other
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 5 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 19
- States / cities
- Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more
- Conditions
- Atopic Dermatitis
- Interventions
- Fluzone® Intradermal (Sanofi Pasteur Inc.)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Subjects Treated With NMP as Part of Their Spine Surgery, Degenerative Disc Disease (DDD)
- Interventions
- NMP
- Device
- Lead sponsor
- Red Rock Regeneration Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Baton Rouge, Louisiana • Shreveport, Louisiana • Salt Lake City, Utah
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, Belimumab 200 mg SC, Standard therapy
- Biological · Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 839 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 68 more
- Conditions
- Major Depressive Disorder
- Interventions
- Genecept Assay
- Device
- Lead sponsor
- Genomind, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chalfont, Pennsylvania
- Conditions
- Autism Spectrum Disorder, Bone Health
- Interventions
- 1. Intranasal oxytocin spray, 2. Intranasal placebo spray, 3. Intranasal Oxytocin spray
- Drug
- Lead sponsor
- Elizabeth Austen Lawson
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia
- Conditions
- Cirrhosis, Hepatic Encephalopathy, Hyponatremia
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Sickle Cell Disease (SCD)
- Interventions
- Crizanlizuamb, Standard of Care
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more
- Conditions
- Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury, Cervical Spinal Cord Injury, Cerebral Palsy
- Interventions
- Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
- Drug
- Lead sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
- Conditions
- Sarcoidosis, Hypercalcemia Due to Sarcoidosis
- Interventions
- ACTHAR Gel (adrenocorticotropic hormone)
- Drug
- Lead sponsor
- Albany Medical College
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Chronic Condition, Chronic Pain, Chronic Disease, Major Depressive Disorder, Post Traumatic Stress Disorder, Anxiety Disorders
- Interventions
- Ketamine
- Drug
- Lead sponsor
- RIVER Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Bigfork, Montana • Helena, Montana
- Conditions
- COVID-19
- Interventions
- Hydroxychloroquine
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Renal Transplant Rejection
- Interventions
- Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
- Drug · Other · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Anifrolumab, Standard of Care
- Drug
- Lead sponsor
- Oklahoma Medical Research Foundation
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more